多替阿巴拉米片上市的日期

It can significantly reduce the medication burden of AIDS patients, thereby improving patients' medication compliance and effectively improving the patients' quality of life and work. Dolutegra abalamib tablets have been approved in more than 100 countries and recommended by many authoritative academic institutions in Europe and the United States as a first-line treatment for newly diagnosed AIDS patients. From the comparison with patients who failed the first-line regimen of RAL (Ascent) and EVG (Evitegravir), the other two integrase inhibitors, the number of drug-resistant mutations in dolutea palamid tablets is significantly less than that of the other two drugs, making it less likely to develop drug resistance. Today we will learn about the release date of Dota Abalami Tablets.

Dolutegra abalami tablets were approved by the FDA on August 27, 2014. On January 20, 2018, ViiV, a joint venture of GlaxoSmithKline, the first complete antiviral treatment drug with dolutegravir (also known as DTG in English) as the core, dolutegravir tablets, was officially launched in China. This is also the first complete single-pill compound treatment plan in the field of HIV treatment in China. Dolutegravir tablets are composed of three ingredients: DTG (DTG) + abacavir (ABC) + lamivudine (3TC). It is a compound treatment agent of integrase inhibitors and nucleoside drugs.

Dolutegra abalami tablets are film-coated tablets, which appear white or off-white after the coating is removed. They are composed of enteric-coated pellets. The general usage and dosage is that this product should be taken under the guidance of a physician with experience in HIV infection. Dosage: Adults and Adolescents (Weighing at least 40kg) For adults and adolescents, the recommended dose of this product is one tablet, once daily. If the weight of adults or adolescents is less than 40kg, this product should not be given because this product is a fixed-dose tablet and the dose cannot be reduced. In addition to using it in compliance with the instructions, if there are special circumstances, it must be used under the guidance of a doctor.

Common adverse reactions of dolutegra tablets include: nausea (12%), insomnia (7%), dizziness (6%) and headache (6%). Patients with abacavir hypersensitivity often experience nausea, vomiting, diarrhea, fever, drowsiness, rash and other symptoms when using this product. If patients experience these symptoms, they should be carefully evaluated for the presence of such a hypersensitivity reaction. Very rarely, erythema multiforme, Stevens-Johnson syndrome, or toxic epidermal necrolysis may occur, and abacavir hypersensitivity cannot be excluded. In such cases, abacavir-containing medicinal products should be permanently discontinued. In individual patients, hypersensitivity reactions, including rash and severe hepatic effects, may occur.

The above is the content of the listing, I hope it can help you!